391 related articles for article (PubMed ID: 9357101)
21. Recent advances in the stereocontrolled synthesis of antisense phosphorothioates.
Lu Y
Mini Rev Med Chem; 2006 Mar; 6(3):319-30. PubMed ID: 16515471
[TBL] [Abstract][Full Text] [Related]
22. Clinical studies of antisense therapy in cancer.
Yuen AR; Sikic BI
Front Biosci; 2000 Jun; 5():D588-93. PubMed ID: 10833467
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
24. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.
Nakata Y; Kim TK; Shetzline S; Gewirtz AM
Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634
[TBL] [Abstract][Full Text] [Related]
25. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotide technology in the development of cancer therapeutics.
Tseng BY; Brown KD
Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
[No Abstract] [Full Text] [Related]
28. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
29. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
30. Sense antisense nonantisense. Can these novel antivirals knock HIV senseless?
Chang HE; Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Feb; 1(1):11-8. PubMed ID: 11362229
[TBL] [Abstract][Full Text] [Related]
31. Oligonucleotides as antivirals: dream or realistic perspective?
Van Aerschot A
Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039
[TBL] [Abstract][Full Text] [Related]
32. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
33. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
34. Antisense inhibition of virus infections.
Kilkuskie RE; Field AK
Adv Pharmacol; 1997; 40():437-83. PubMed ID: 9217933
[TBL] [Abstract][Full Text] [Related]
35. Patent review: therapeutic applications for antisense oligonucleotides 1999-2000.
Orr RM; O'Neill CF
Curr Opin Mol Ther; 2000 Jun; 2(3):325-31. PubMed ID: 11249627
[TBL] [Abstract][Full Text] [Related]
36. Antisense molecules: A new class of drugs.
Potaczek DP; Garn H; Unger SD; Renz H
J Allergy Clin Immunol; 2016 May; 137(5):1334-46. PubMed ID: 27155029
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligonucleotides for therapeutic intervention.
Eck SL; Nabel GJ
Curr Opin Biotechnol; 1991 Dec; 2(6):897-904. PubMed ID: 1367966
[TBL] [Abstract][Full Text] [Related]
38. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
Chen HX
Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
[No Abstract] [Full Text] [Related]
39. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
40. Nucleic acid-based drugs against emerging zoonotic viruses.
Wong JP
Future Med Chem; 2015; 7(13):1709-19. PubMed ID: 26399689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
